Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

• Status: Terminated
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase II double blind trial to evaluate the effects of the AMPA, glutamte antagonist, topiramate on levodopa-induced dyskinesia in Parkinson's disease

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Levodopa; Topiramate

Criteria

Inclusion Criteria:

• UK PD Society Brain Bank criteria for the diagnosis of idiopathic PD.

• Patients with stable levodopa-induced dyskinesias present greater than 25% of the day (Unified Parkinson's Disease Rating Scale (UPDRS), item 32, rating > 2) and be moderately to completely disabling (UPDRS item 33, rating > 2).

• All anti-parkinsonian medications must be stable for at least one month prior to study enrollment.

Exclusion Criteria:

• Include prior surgery for PD

• Hoehn and Yahr score of 5 when "off"

• History of nephrolithiasis

• Renal impairment

• Liver disease

• Pregnancy

• Premenopausal females and males not using adequate contraception

• Cognitive impairment (Mini Mental State Exam score less than 24)

• History of glaucoma or seizures

• Use of other antiepileptic drugs

• Amantadine

• Carbonic anhydrase inhibitors

• Digoxin

• Metformin

• Or illicit drugs